BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

CAPS Rating: 3 out of 5

A biopharmaceutical company that is utilizing its licensed, owned and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties.

Results 1 - 20 of 36 : 1 2 Next »

Recs

0
Member Avatar manirg (41.95) Submitted: 3/9/2014 10:28:55 PM : Outperform Start Price: $9.03 BDSI Score: -17.97

Undervalued. FDA approved drug and more coming. Proven delivery
system. A 5-10x potential.

Recs

1
Member Avatar SkepBioInvestor (88.74) Submitted: 1/20/2014 9:13:18 AM : Outperform Start Price: $6.73 BDSI Score: +9.18

Positive Phase 3 data of BEMA Buprenorphine

Recs

1
Member Avatar chris293 (87.14) Submitted: 9/17/2013 9:38:22 PM : Outperform Start Price: $5.41 BDSI Score: +27.95

Almost everyone picked this.

Recs

0
Member Avatar TerryHoodSr (49.05) Submitted: 8/6/2013 10:20:17 PM : Outperform Start Price: $6.95 BDSI Score: +3.99

growth potential

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/6/2013 7:22:00 PM : Underperform Start Price: $4.49 BDSI Score: -54.80

Short. Biotech, revs down 90%

Recs

1
Member Avatar tunafizzle (87.89) Submitted: 3/27/2013 3:08:43 PM : Outperform Start Price: $4.13 BDSI Score: +59.92

Get it while its still cheap. Reckitt Benckiser recently stopped production of their "generic" suboxone tablets, leaving patients with no choice but to buy their still brand name sublingual film at double the price. BDSI is hoping to come out with an alternative to suboxone and can pull tons of customers away. However what could make this small cap really explode is if and when they get approval for a buprenorphine only formula that wouldn't be subject to DATA2000 regulations. Currently <5% of doctors are legally allowed to prescribe suboxone(buprenorphine/naloxone) and Reckitt's biggest revenue source is still suboxone. If BDSI can get approval for non-restricted buprenorphine they will be bringing in billions for a long time.
Bottom line:
This small cap pharma has some risk but unlike similar companies they have more than one bet in their pipeline. Generic suboxone is their "safe" bet and could easily send this stock over 10 and give steady growth, approval for buprenorphine (unrestricted) would send this stock through the roof. If you have an extra hundred or two to risk, put it here.

Recs

0
Member Avatar Herbert7946 (< 20) Submitted: 7/9/2012 2:15:18 PM : Outperform Start Price: $5.00 BDSI Score: +10.08

huge profits on the way

Recs

3
Member Avatar zzlangerhans (99.74) Submitted: 12/28/2011 1:52:17 AM : Outperform Start Price: $0.80 BDSI Score: +779.86

BioDelivery did some pretty significant damage to my brokerage account and my CAPS score. I can't do much about the former, but I can strive for some redemption in the latter. BEMA buprenorphine is a clinical failure and BEMA Fentanyl is a commercial failure. The last man standing would appear to be BEMA buprenorphine/naloxone, headed for a pivotal comparative pharmacokinetic study versus Suboxone. It's hard to say what exactly a pivotal comparative pharmacokinetic study is, except that it seems to be a way for the company to circumvent a direct clinical efficacy comparison study with Suboxone.

BioDelivery thinks the FDA is cool with that, but they're going to take the prudent step of meeting with them before initiating the study. Based on BioDelivery's prior accomplishments, I wouldn't put much stock in their prediction of the FDA's mindset. This is hopefully a short-term green thumb on a deep dip, eventually to be followed by a red thumb to bankruptcy.

Recs

0
Member Avatar D0min0 (45.70) Submitted: 10/5/2011 7:57:21 AM : Outperform Start Price: $0.99 BDSI Score: +582.21

Recently really beaten down by the failure of early phase 3 clinical trial results showing its pain drug BEMA Buprenorphine missed the primary target of its study, but Buprenorphine is already a Food and Drug Administration-approved drug for pain treatment. BDSI has $21 million in cash so a revised study is underway. Good company, well run, hit a bump in the road.

Recs

0
Member Avatar Closed4Good (< 20) Submitted: 6/25/2011 2:41:38 PM : Outperform Start Price: $3.45 BDSI Score: +67.81

A previously unproven company but with a practical piece of industry regulatory experience providing the perfect launch pad for a proven proprietary application process, poised to pick up the pace with partnerships and an particularly pleasing pipeline!

Recs

0
Member Avatar hslojewski (< 20) Submitted: 3/21/2011 5:46:47 PM : Outperform Start Price: $3.28 BDSI Score: +82.13

Lots of promise, could be a year off, maybe more, but good things will happen.

Recs

0
Member Avatar motleyjabberwock (< 20) Submitted: 3/3/2011 1:18:22 PM : Outperform Start Price: $3.52 BDSI Score: +70.34

1.6 PE, revenue growth of 675% over 3 years, and 290 ROE. Delicious fundamentals.

Recs

0
Member Avatar pageboy67 (61.10) Submitted: 12/8/2010 11:14:42 AM : Outperform Start Price: $2.80 BDSI Score: +112.68

Declining short interest in November will drive stock up.

Recs

0
Member Avatar sleeplessny (< 20) Submitted: 11/16/2010 11:32:02 PM : Outperform Start Price: $2.87 BDSI Score: +100.39

check out the balance sheet
it's a gold mine

Recs

0
Member Avatar ebitdat (< 20) Submitted: 9/23/2010 10:47:25 AM : Outperform Start Price: $2.80 BDSI Score: +99.83

Proven product and low valuation. Concerns about cash flow and liquidity are mitigated by proven partnership ability and able management

Recs

0
Member Avatar cibient (24.20) Submitted: 8/30/2010 2:36:07 AM : Outperform Start Price: $2.26 BDSI Score: +150.04

MFI screener. CEO bought shares on open market at prices higher than the low $2s. Basic valuation ratios look out of whack (P/E, etc.) and may reflect its biotech+microcap nature

Recs

0
Member Avatar 2gud2btrue (84.77) Submitted: 8/11/2010 12:25:21 PM : Outperform Start Price: $2.29 BDSI Score: +153.25

Target $6 - $9. Profit making Bio firm what else do you want.
11-08-10. Price $ 2.30

Recs

0
Member Avatar herbertslojewski (71.99) Submitted: 7/27/2010 7:34:55 PM : Outperform Start Price: $2.30 BDSI Score: +152.75

cuz I likes it

Recs

2
Member Avatar mogruith (99.38) Submitted: 6/18/2010 8:45:39 AM : Outperform Start Price: $2.73 BDSI Score: +104.63

Beaten down, recent insider buying, solid balance sheet.

Recs

1
Member Avatar whomonkyoulus (28.65) Submitted: 6/11/2010 5:30:12 PM : Outperform Start Price: $2.70 BDSI Score: +105.67

Cluster of insider purchases at higher prices in the last month or two.

Results 1 - 20 of 36 : 1 2 Next »

Featured Broker Partners


Advertisement